Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer

Triple-negative breast cancer (TNBC) afflicts women at a younger age than other breast cancers and is associated with a worse clinical outcome. This poor clinical outcome is attributed to a lack of defined targets and patient-to-patient heterogeneity in target antigens and immune responses. To addre...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Christopher D. Pack, Ramireddy Bommireddy, Luis E. Munoz, Jaina M. Patel, Erica N. Bozeman, Paulami Dey, Vijayaraghavan Radhakrishnan, Vincent F. Vartabedian, Kalpana Venkat, Sampath Ramachandiran, Shaker J. C. Reddy, Periasamy Selvaraj
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-12-01
Subjects:	cancer vaccine immunotherapy ctla-4 cd80 il-12 protein transfer tumor membrane vesicles glycosyl phosphatidylinositol anchor
Online Access:	http://dx.doi.org/10.1080/21645515.2020.1754691